Duodenal and gallbladder metastasis of regressive melanoma: a case report and review of the literature

Hamza Ettahri1,2, Fadwa Elomrani1,2, Mustapha Elkabous1,2, Mouna Rimani3, Saber Boutayeb1,2, Hind Mrabti1,2, Hassan Errihani1,2

1Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco; 2Faculté de Médecine et de Pharmacie de Rabat, Université Mohamed V Souissi, Rabat 8007, Morocco; 3Centre de Pathologie Hassan, Rabat, Morocco

Correspondence to: Hamza Ettahri. Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco. Email: hamza-17@hotmail.com.

Background: Malignant melanoma involving the gastrointestinal (GI) tract may be primary or metastatic. Small bowel is the commonest site of GI metastases from cutaneous malignant melanoma, metastatic lesion in the gallbladder is extremely rare.

Case presentation: This case report describes the presentation of metastatic melanoma in duodenum and gallbladder. A 45-year-old man has presented melena with intermittent abdominal pain. On physical examination we found a small lesion between the fourth and fifth toes, associated with inguinal lymph node. An Abdominal ultrasound revealed diffuse duodenal thickening. Upper endoscopy was performed and discovered an ulcerative lesion in the second part of the duodenum. The biopsy with immunohistochemical stains was in favor of a duodenal location of melanoma. Computed tomography (CT) revealed many circumferential thickening of ileal loops associated with a nodular lesion in the anterior wall of the gallbladder. The patient was treated by palliative chemotherapy.

Discussion: Malignant melanoma of the GI tract may be primary or secondary. The small bowel is the most affected, but it’s rare in the gallbladder. The clinical presentation can mimic the other intestinal tumors, and the diagnosis is based on imaging; CT scan and GI endoscopy have a key role on the diagnosis, and the treatment depends on the location and the number of lesions.

Conclusions: Metastases of melanoma in the GI tract are uncommon, the diagnosis must be suspected in any patient with a history of melanoma with digestive signs.

Keywords: Melanoma; metastases; duodenum; gallbladder

Submitted Mar 05, 2015. Accepted for publication Mar 10, 2015.
View this article at: http://dx.doi.org/10.3978/j.issn.2078-6891.2015.048

Introduction

Gastrointestinal (GI) malignant melanoma is an unusual clinical entity. Patients often present the similar clinical symptoms like other common tumors in this site, and there are no specific radiological features. It may be primary or metastatic (1,2).

Cutaneous melanoma, whose incidence is increasing, is the most common cause of metastasis in the GI tract (3-8). Metastasis to the GI tract is often seen in the small intestine, followed by the colon, stomach, and rectum, but it's rare in the esophagus and in the gallbladder (9-12).

We describe a case of a 45-year-old male with duodenal and gallbladder metastasis of malignant melanoma.

Case presentation

We report a case of a 45-year-old man, without medical history, who presents intermittent abdominal pain associated with melena for the past five months.

On physical examination we found a small submillimeter lesion between the fourth and fifth toes, associated with ipsilateral inguinal lymph node measuring 40 mm × 35 mm.
Biopsy of these lesions confirmed diagnosis of melanoma with many sites of involution (Figure 1).

An abdominal ultrasound revealed diffuse duodenal thickening, with deep abdominal lymph nodes.

A gastroduodenoscopy was performed and discovered an ulcerative lesion in the second part of the duodenum (Figure 2). Biopsy with immunohistochemical stains was in favor of a duodenal location of melanoma. Indeed, S100 protein, HMB-45 antibodies, and Melan A staining were strongly positive, thus confirming a diagnosis of duodenal melanoma (Figure 3).

An abdominal computed tomography (CT) scan has found many circumferential thickening of ileal loops with the presence of peri-intestinal, peri-renal and inguinal lymph nodes, associated with a nodular lesion in the anterior wall of the gallbladder (Figure 4).

The case was discussed in multidisciplinary concertation meeting, and we decided to treat the patient by palliative chemotherapy. Our patient received a regimen of palliative chemotherapy based on dacarbazine (DTIC). The assessment after three cycles was in favor of stable disease.

**Discussion**

Melanoma is a malignant tumor which develops from melanocytes, a pigmented, dendritic like cells, present mainly in the skin, eyes, meninges, and GI mucosa, from the mouth to the anal canal (13). Over 90% of melanoma cases are observed on the skin (14). Melanoma is a relatively rare tumor comprising 1-3% of all tumors and exhibits an unusual tendency to metastasize to the GI tract (12,15).

The incidence of melanoma is increasing in Europe and the United States, and the mortality related to unresectable or metastatic melanoma remains high. Globally, 132,000 new cases of melanoma are diagnosed and an estimated 48,000 persons die from advanced melanoma each year (16).

Malignant melanoma of the GI tract may be primary or secondary (14). Metastases are not uncommon, the small bowel is the most affected, followed by the stomach, large bowel, but it’s rare in esophagus and in the gallbladder. It can appear in a few years after treatment of primary melanoma. These lesions are often clinically occult and are diagnosed in 1-9% of cases (7,8). From 1963 to 2000, Wagner et al. reported the review of six cases of primary malignant melanoma of common bile duct (17).

It is difficult to differentiate primary intestinal melanoma from metastatic melanoma, because primary lesion tends to regress and disappear. In addition, melanoma can mimic other neoplasia and may create a major diagnostic challenge when it’s located in intra-abdominal area (18,19).

Almost all GI melanoma are metastatic from cutaneous,
ocular, or anal primary melanomas (20). However, melanoma can arise *de novo* from certain areas of the GI system (21) and may sometimes be hidden by a rectal polyp (22). In total 2-4% of patients with melanoma will be diagnosed with GI metastasis during the course of their disease (20).

The post-mortem examination of patients with melanoma reveals an invasion of the digestive tract in 50% to 60% cases (7,8). However, an ante-mortem diagnosis of metastasis on the digestive tract is only in 1-9% of cases.

**Figure 3** Histological examination of the duodenal lesion (hematoxylin-eosin) with immunohistochemical stains. (A) Duodenal round cells proliferation (×40); (B) details of cells (×400); (C) the tumor cells were positive for Melan-A in cytoplasm (×100); (D) the tumor cells were positive for HMB45 in cytoplasm (×400).

**Figure 4**Computed tomography scan of the abdomen reveals a circumferential thickening of the duodenum (red arrow in A) and gallbladder location of melanoma (red arrow in B).
The clinical presentation is like other intestinal tumors, they may be accompanied by abdominal pain, upper or lower GI tract bleeding, anemia, weight loss, intestinal obstruction, perforation or intussusceptions. The classic presentation is intestinal intussusceptions which causes obstruction, and may require urgent surgical intervention (14).

A Belgian series, concerning only ten patients, shows that metastases in the GI tract are often unique and always visible on morphological examinations (8).

The diagnosis based on imaging, routine barium examinations, CT scan of the abdomen, ultrasound and PET imaging are used to locate sites of metastasis. The CT scan has 60-70% sensibility in detection of metastasis. In ultrasounds examination, these lesions present as one or more submucosal nodes, with hyperechoic central ulceration (14,23).

The GI endoscopy should be the procedure of choice to diagnose malignant melanoma of GI tract. We can describe three types of malignant melanoma at the endoscopy: the ulcerated melanoma resulting from mucosal fold, sub-mucosal masses with ulceration and tumoral lesions with necrosis and melanosis. However, neoplasia may be completely amelanotic with variable cytological appearance.

Immunohistochemical stains are needed to confirm diagnosis of malignant melanoma; the S100 sensitivity varies between 33-100%, HMB-45 antibodies has sensitivity between 80-97%, but the specificity is high (100%) (24).

Management of GI malignant melanoma depends on the location and number of the lesion. The optimum treatment for malignant melanoma is an extensive and curative surgery, if possible, because other therapeutics methods including adjuvant radiotherapy, chemotherapy and immunotherapy cannot offer definite treatment outcome. The time of diagnosis and the presence of metastases are the most important prognostic factors (25,26).

In case of single lesion, surgical treatment offers an efficient relief of symptoms and, in rare cases, a relatively extended survival (8).

The discovery of BRAF, NRAS, PTEN and KIT alterations in melanoma has allowed the emergence of various rational therapeutic approaches. Indeed, the management of unresectable or metastatic melanoma will be based on anticancer drugs targeting BRAF or c-kit.

Prognosis of malignant melanoma of GI tract is very poor because of difficult to diagnosis. The median overall survival time in patients with metastatic melanoma is 7.5 months, with a 5 years survival of 6%. Patients with malignant melanoma in the GI tract have a duration of survival at 12.5 months with a 5-year survival of 14% (14,27).

Conclusions

Metastases of melanoma in the GI tract are uncommon, and should be suspected in patient with a history of melanoma with symptoms of the digestive system. The presence of these signs should carry out morphological examinations including upper endoscopy with biopsy.

Any treatment decisions should be done in a multidisciplinary meeting, in case of unresectable or metastatic melanoma, only palliative treatment can be considered.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


